A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
Public ClinicalTrials.gov record NCT05044234. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects With Moderate to Severe Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study assessed how safe and effective cedirogant (ABBV-157) was compared to placebo in adult participants with moderate to severe psoriasis. Efficacy and safety-related measurements assessed disease activity in participants with plaque psoriasis. Cedirogant (ABBV-157) is an investigational drug being developed for the treatment of chronic plaque psoriasis. Participants were put into 1 of 4 groups, called treatment arms and each group received a different treatment. There was a 1 in 4 chance that participants were assigned to placebo. Participants received oral daily doses of cedirogant or placebo capsules for 16 weeks. There may have been a higher burden for participants in this study compared to usual standard of care. Participants attended regular visits per routine clinical practice. The effect of the treatment was checked by medical assessments, checking for side effects, and questionnaires.
Study identification
- NCT ID
- NCT05044234
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 156 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2021 (Actual)
- Primary completion
- Nov 30, 2022 (Actual)
- Completion
- Nov 30, 2022 (Actual)
- Last update posted
- Nov 29, 2023
2021 – 2022
United States locations
- U.S. sites
- 37
- U.S. states
- 22
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Department of Dermatology /ID# 238563 | Birmingham | Alabama | 35233 | — |
| Medical Dermatology Specialist /ID# 238518 | Phoenix | Arizona | 85006-2722 | — |
| Arkansas Research Trials, LLC /ID# 238687 | North Little Rock | Arkansas | 72117 | — |
| Encino Research Center /ID# 245950 | Encino | California | 91436 | — |
| Velocity Clinical Research, Inc. /ID# 239536 | North Hollywood | California | 91606 | — |
| Medderm Associates /ID# 238834 | San Diego | California | 92103 | — |
| Lakes Research, LLC /ID# 238831 | Miami | Florida | 33014 | — |
| Florida International Rsrch cr /ID# 245959 | Miami | Florida | 33173 | — |
| Lenus Research & Medical Group /ID# 238695 | Sweetwater | Florida | 33172 | — |
| Advanced Clinical Research Institute /ID# 238697 | Tampa | Florida | 33607-6429 | — |
| Clinical Research Trials of Florida, Inc. /ID# 238709 | Tampa | Florida | 33607 | — |
| ForCare Clinical Research /ID# 238856 | Tampa | Florida | 33613-1244 | — |
| Cleaver Medical Group Dermatology - Dawsonville /ID# 246327 | Dawsonville | Georgia | 30534-6369 | — |
| Marietta Dermatology Clinical Research /ID# 238679 | Marietta | Georgia | 30060-1047 | — |
| Arlington Dermatology /ID# 238701 | Rolling Meadows | Illinois | 60008 | — |
| Dawes Fretzin, LLC /ID# 238704 | Indianapolis | Indiana | 46256 | — |
| Zel Skin & Laser Specialists - Edina /ID# 238714 | Edina | Minnesota | 55424-1200 | — |
| Skin Specialists, PC /ID# 238514 | Omaha | Nebraska | 68144 | — |
| Forest Hills Dermatology Group /ID# 238708 | Kew Gardens | New York | 11415 | — |
| Buffalo Medical Group /ID# 239068 | Williamsville | New York | 14221 | — |
| Darst Dermatology /ID# 238677 | Charlotte | North Carolina | 28277 | — |
| Wilmington Dermatology Center /ID# 246445 | Wilmington | North Carolina | 28403 | — |
| Univ Hosp Cleveland /ID# 245953 | Cleveland | Ohio | 44106 | — |
| Dermatologists of Southwest Ohio, Inc /ID# 238939 | Mason | Ohio | 45040-4520 | — |
| Oregon Dermatology and Research Center /ID# 238823 | Portland | Oregon | 97210 | — |
| University of Pittsburgh MC /ID# 246170 | Pittsburgh | Pennsylvania | 15260 | — |
| Clinical Partners, LLC /ID# 238620 | Johnston | Rhode Island | 02919 | — |
| Clinical Research Center of the Carolinas /ID# 238827 | Charleston | South Carolina | 29407 | — |
| Health Concepts /ID# 238510 | Rapid City | South Dakota | 57702 | — |
| Tennessee Clinical Research Center /ID# 238682 | Nashville | Tennessee | 37215-2885 | — |
| Arlington Research Center, Inc /ID# 244171 | Arlington | Texas | 76011 | — |
| Orion Clinical Research /ID# 238619 | Austin | Texas | 78759-4100 | — |
| Bellaire Dermatology Associates /ID# 247865 | Bellaire | Texas | 77401 | — |
| Center for Clinical Studies - Houston (Binz) /ID# 243700 | Houston | Texas | 77004-8097 | — |
| Progressive Clinical Research /ID# 238565 | San Antonio | Texas | 78229 | — |
| Dermatology Specialists of Spokane /ID# 238809 | Spokane | Washington | 99202 | — |
| West Virginia Research /ID# 238517 | Morgantown | West Virginia | 26505-0589 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05044234, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2023 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05044234 live on ClinicalTrials.gov.